Selected Publications


Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, Jibril A, Di Palma F, Collins A, Bowles KM, Rushworth SA.

Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells.

Haematologica. 2020 Mar 19:haematol.2019.242974.


Hellmich C, Moore JA, Bowles KM, Rushworth SA. Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. Frontiers in Oncology. 2020 Feb 25;10:230.


Mistry JJ, Marlein CR, Moore JA, Hellmich C, Wojtowicz EE,

Smith JGW, Macaulay I,  Sun Y, Morfakis A, Patterson A, Horton RH, Divekara D, Morris CJ, Haestier A, Di Palma F, Beraza N, Bowles KM, Rushworth SA. ROS mediated PI3K activation drives Mitochondrial Transfer from Stromal Cells to Hematopoietic Stem Cells in Response to Infection. Proc Natl Acad Sci U S A. 2019 Nov 14. pii: 201913278. doi: 10.1073/pnas.1913278116.  

Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, Zhou Z, Auger MJ, Bowles KM, Rushworth SA. CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Research. 2019 May 1;79(9):2285-2297.

Abdul-Aziz AM, Sun Y, Hellmich C, Marlein CR, Mistry J, Forde E, Piddock RE, Shafat MS, Morfakis A, Mehta T, Di Palma F, Macaulay I, Ingham CJ, Haestier A, Collins A, Campisi J, Bowles KM, Rushworth SA. Acute myeloid leukemia induces pro-tumoral p16INK4a driven senescence in the bone marrow microenvironment. Blood. 2019 Jan 31;133(5):446-456.


Marlein CR, Zaitseva L, Piddock RE, Raso-Barnett L, Scott MA, Ingham CJ, Collins A, Bowles KM, Rushworth SA. PGC-1α driven mitochondrial biogenesis in stromal cells underpins mitochondrial trafficking to leukemic blasts. Leukemia. 2018 Sep;32(9):2073-2077.

Piddock RE, Marlein CR, Abdul-Aziz A, Shafat MS, Auger MJ, Bowles KM, Rushworth SA. Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC. J Hematol Oncol. 2018 May 16;11(1):66.


Abdul-Aziz AM, Shafat MS, Sun Y, Marlein CR, Piddock RE, Robinson SD, Edwards DR, Zhou Z, Collins A, Bowles KM, Rushworth SA. HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia. Oncogene. 2018 May;37(20):2676-2686.


Sun Y, Abdul Aziz A, Bowles K, Rushworth S. High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Cancer Letters. 2018 Jan 1;412:37-45.


Marlein CR, Zaitseva L, Piddock RE, Robinson S, Edwards D, Shafat MS, Zhou Z, Lawes M, Bowles KM, Rushworth SA. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood. 2017 Oct 5;130(14):1649-1660.

Piddock RE, Loughran N, Marlein CR, Robinson SD, Edwards DR, Yu S, Pillinger GE, Zhou Z, Zaitseva L, Auger MJ, Rushworth SA, Bowles KM. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment. Blood Cancer Journal. 2017 Mar 10;7(3):e539.


Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, Piddock RE, Fenech M, Zaitseva L, Abdul-Aziz A, Turner J, Watkins JA, Lawes M, Bowles KM, Rushworth SA. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017 Mar 9;129(10):1320-1332.


Abdul-Aziz AM, Shafat MS, Mehta TK, Di Palma F, Lawes MJ, Rushworth SA, Bowles KM. MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia. Cancer Research. 2017 Jan 15;77(2):303-311.



Pillinger G, Loughran NV, Piddock RE, Shafat MS, Zaitseva L, Abdul-Aziz A, Lawes MJ, Bowles KM, Rushworth SA. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795.

Wittmann A, Lamprinaki D, Bowles KM et al. Dectin-2 Recognizes Mannosylated O-antigens of Human Opportunistic Pathogens and Augments Lipopolysaccharide Activation of Myeloid Cells. J Biol Chem. 2016 Aug 19;291(34):17629-38.



Rushworth SA, Pillinger G, Abdul-Aziz A, Piddock R, Shafat MS, Murray MY, Zaitseva L, Lawes MJ, MacEwan DJ, Bowles KM. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. Lancet Haematology. 2015 May;2(5):e204-11.


Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, Rushworth SA. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. Scientific Reports. 2015 Aug 21;5:12949.


Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle. 2015;14(14):2367-75.


Shah NM, Zaitseva L, Bowles KM, MacEwan DJ, Rushworth SA. NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. Cell Death & Differentiation. 2015 Apr;22(4):654-64.



Zaitseva L, Murray MY, Shafat MS, Lawes MJ, MacEwan DJ, Bowles KM, Rushworth SA. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget. 2014 Oct 30;5(20):9930-8.


Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma. Biochemical Society Transactions. 2014 Aug;42(4):804-8.


Rushworth SA, Murray MY, Zaitseva L, Bowles KM, Macewan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014 Feb 20;123(8):1229-38.



Rushworth SA, MacEwan DJ, Bowles KM. Ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine. 2013 Sep 26;369(13):1277-8.


Shah NM, Rushworth SA, Murray MY, Bowles KM, MacEwan DJ. Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget. 2013 Aug;4(8):1130-42.


Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle. 2013 Jul 1;12(13):2144-53.


Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signaling. 2013 Jan;25(1):106-12.



Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute

myeloid leukemia is driven by NF-κB and underlies its chemo-resistance. Blood. 2012 Dec 20;120(26):5188-98.


Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle. 2012 Jun 15;11(12).



Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Research. 2011 Mar 1;71(5):1999-2009.



Rushworth SA, Bowles KM, Raninga P, MacEwan DJ. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Research. 2010 Apr 1;70(7):2973-83.

Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget. 2010 Sep;1(5):359-66.

Norwich Medical School

University of East Anglia, UK

© 2018 by Stuart Rushworth and Kris Bowles

Proudly created with